This product has been discontinued in the North American market.  If you have interest in purchasing a legacy system or compatible reagents, please contact us.

Multiplate® GpIIbIIIa Antagonist is a reagent kit for use as quality control in platelet aggregation studies on the Multiplate® Analyzer. The GPIIb/IIIa Antagonist blocks the GPIIb/IIIa receptor and leads to abolished aggregation in all Multiplate® tests.

GpIIb/IIIa antagonist inhibits the fibrinogen receptors of the platelets thus preventing their adhesion onto the sensor wires of the Multiplate® test cell. The reagent is employed in combination with the Multiplate activating reagents TRAPtest, ASPItest, COLtest and ADPtest. Addition of GpIIb/IIIa antagonist to the blood sample leads to strongly reduced aggregation in TRAPtest, ADPtest, ASPItest and COLtest.

Reagents, Storage and Stability

  • MP0520: Multiplate® GpIIb/IIIa antagonist, synthetic GpIIb/IIIa antagonist (molecular weight 495 g/mol in a concentration of 50 µg/ml), 1 x 0.5 ml, liquid, ready for use.
  • MP0280: Multiplate® GpIIb/IIIa antagonist, synthetic GpIIb/IIIa antagonist (molecular weight 495 g/mol in a concentration of 50 µg/ml), 3 x 0.5 ml, liquid, ready for use.
Unopened vials of the GpIIb/IIIa antagonist are stable until the expiry date printed on the vial label when stored stored at 2-8°C. Vials should be stored in an upright position. Stable 30 days after opening when stored at 2-8°C.

GpIIb/IIIa antagonist contains a synthetic inhibitor of the platelet GpIIb/IIIa receptor with a molecular weight of 495 g/mol at a concentration of 50 µg/ml. Blocking the GpIIb/IIIa receptor leads to abolished aggregation in the Multiplate tests. This allows the assessment of a positive control (strongly inhibited aggregation) in all tests. Furthermore unspecific effects of chemicals present in the sample onto the Multiplate® sensors can be elucidated (e.g. addition of oxidative substances into the blood).

Normally when the GpIIb/IIIa antagonist is added to the sample no significant impedance change during the analysis is recorded, because the binding of platelets onto the sensor wires is blocked. If a significant increase or decrease of impedance is still recorded when the GpIIb/IIIa antagonist is added to the sample, this suggests unspecific direct effects of substances in the blood or substances in reagents (that were not developed by Verum Diagnostica GmbH) onto the sensor wires (e.g. oxidating effects).